Cargando…

Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial

Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawangroj, Nicharat, Budkaew, Jiratha, Chumworathayi, Bandit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809885/
https://www.ncbi.nlm.nih.gov/pubmed/33510892
http://dx.doi.org/10.12688/f1000research.20662.1
_version_ 1783637206462627840
author Sawangroj, Nicharat
Budkaew, Jiratha
Chumworathayi, Bandit
author_facet Sawangroj, Nicharat
Budkaew, Jiratha
Chumworathayi, Bandit
author_sort Sawangroj, Nicharat
collection PubMed
description Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001.
format Online
Article
Text
id pubmed-7809885
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-78098852021-01-27 Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial Sawangroj, Nicharat Budkaew, Jiratha Chumworathayi, Bandit F1000Res Research Article Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001. F1000 Research Limited 2019-10-30 /pmc/articles/PMC7809885/ /pubmed/33510892 http://dx.doi.org/10.12688/f1000research.20662.1 Text en Copyright: © 2019 Sawangroj N et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sawangroj, Nicharat
Budkaew, Jiratha
Chumworathayi, Bandit
Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title_full Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title_fullStr Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title_full_unstemmed Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title_short Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
title_sort efficacy of curcuma longa in treatment of postprandial distress syndrome: an open-label randomized-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809885/
https://www.ncbi.nlm.nih.gov/pubmed/33510892
http://dx.doi.org/10.12688/f1000research.20662.1
work_keys_str_mv AT sawangrojnicharat efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial
AT budkaewjiratha efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial
AT chumworathayibandit efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial